Pharmacogenetic study to predicting clinical response of oxaliplatin in patients with advanced colorectal cancer

点击翻译按钮获取中文摘要

Susceptibility to oxaliplatin-induced neuropathy differs greatly among patients. In this study, we investigated the associations between oxaliplatin-induced neuropathy and the following polymorphisms : glutathione S-transferase p (GSTP1) Ile^<105>Val, and glyoxylate aminotransferase (AGXT) Pro^<11>Leu and AGXT Ile^<340>Met. Eighty-two Japanese patients with histologically confirmed colorectal cancer who received at least six cycles of the modified FOLFOX6 (m-FOLFOX6) regimen were enrolled.There were more patients carrying at least one GSTP1^<105>Val allele among the group with grade 2/3 neuropathy han among the group with grade 1 neuropathy although the difference was not statistically significant (41% vs 24%, P=0.098). There were similar numbers of patients carrying at least one AGXT^<105>Met allele in the grade 2/3 neuropathy and grade 1 neuropathy groups (16% vs 13% ; P=0.725). The AGXT^<11>Leu allele was not found in any of our patients or controls.